Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer. In this educational program, these experts discuss the latest advances in integrating oral SERDs and emerging combination strategies into the care of patients with HR+/HER2– metastatic breast cancer. Through interactive, case-based discussions, participants gain practical strategies for treatment selection and sequencing, choosing between monotherapy and combination approaches based on patient-specific factors, applying clinical trial and real-world evidence, and proactively managing adverse events to optimize patient outcomes.
This educational activity is an archive of the live presentation
held on July 9, 2026.
Target Audience
This
educational program is primarily directed toward a global audience of
community-based medical oncologists, surgical oncologists, advanced practice
providers, nurses, and other healthcare providers involved in the treatment of
metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify approved and emerging oral SERDs for the management of HR+/HER2– breast cancer
- Assess emerging clinical trial and real-world evidence to gain practical insights into the appropriate use of oral SERD-based treatment strategies for patients with HR+/HER2– MBC
- Integrate clinical trial data, real-world evidence, and patient- and disease-specific factors to inform personalized treatment decisions for patients with HR+/HER2– MBC
- Apply evidence-based approaches to anticipate, monitor, and manage adverse effects associated with targeted therapies for patients with HR+/HER2– MBC
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Head, Division of Hematology and Oncology
Senior Vice President, Clinical Research Division
Department of Medicine
UW Medicine
Fred Hutch Cancer Center
Seattle, WA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Akari Therapeutics, ALX Oncology, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Boundless Bio, BriaCell, BridgeBio, Daiichi Sankyo, Ellipses Pharma, EMBioSys, Gilead Sciences (breast cancer council), Jazz Pharmaceuticals, Lilly Oncology, Luminate Medical, Mersana Therapeutics, Myricx Bio, Novartis (unpaid), Prelude Therapeutics, Roche (global); Grant/Research Funding: AstraZeneca/Daiichi Sankyo (B12), Novartis (PHASE I), Stemline Therapeutics/Menarini Group (ELEVATE); Royalty or Patent Benefits: Elsevier (Cancer Treatment Reviews editorial services), McGraw Hill (Current Medical Diagnosis and Treatment textbook), SAGE Publications (Therapeutic Advances in Medical Oncology editorial services), Wolters Kluwer (UpToDate); Ownership interests in privately held companies: ROMTech (stocks — orthopedic device, not cancer related); Steering Committee: Alliance Foundation, Daiichi Sankyo, Genentech/Roche, Gilead Sciences, InClin/Atossa trial, Jazz Pharmaceuticals, Novartis, Quantum Leap, Roche (paid to UW), Seagen/Pfizer, Stemline Therapeutics
Shaina Rozell, MD, MPH
Medical Director Hereditary Cancer Clinic
Affiliated Oncologist, LLC
Chicago Ridge, IL
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca Pharmaceuticals, Gilead Sciences
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved,
or off-label use of drugs. Learners are advised to consult prescribing
information for any products discussed. The information provided in this
accredited activity is for continuing education purposes only and is not meant
to substitute for the independent clinical judgment of a health care
professional relative to diagnostic, treatment, or management options for a
specific patient’s medical condition. The opinions expressed in the content are
solely those of the individual faculty members and do not reflect those of PER
or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
